Ass. Prof. Elisabeth Riedl – Austria
Associate Professor
Department of Dermatology
Medical University of Vienna
Waehringer Guertel 18-20
A-1090 Vienna Austria
phone +43+1+40400 7701
Fax +43+140400 7699
e-mail: elisabeth.riedl@meduniwien.ac.at
Hospital Appointments/Affiliations:
04/05-06/07 Staff physician, Department of Dermatology, Division of General Dermatology, Medical University Vienna, Austria
07/07-ongoing senior staff physician, Department of Dermatology, Division of General Dermatology, Medical University Vienna, Austria
01/2011-12/2012 Visiting Professor, Department of Dermatology, Mount Sinai Hospital, New York, NY, USA
(Sabbatical leave from the Medical University of Vienna since 11/2011)
Training Record
06/04/2004 Austrian Board Examination in Dermatology, Austrian Medical Association
07/02/2004 “Habilitation” in Dermatology (Venia Docendi), Medical University of Vienna, Vienna, Austria
12/06/2008 International Board Certifying Examination in Dermatopathology, International Society of Dermatopathology, Frankfurt, Germany
03/2011 Recognition of the specialization in dermatopathology by the Austrian Medical Association
Awards
1995 Hans-and-Blanca Moser Award
2001 Visiting Fellow Award, Fogarty Center, Bethesda, MD, USA
2008 Visiting Fellowship Award, Ackerman Academy of Dermatopathology, New York, NY, USA
Membership in Medical Associations
Austrian Society of Dermatology and Venereology
International Society of Dermatopathology
Editor Activities
2006-ongoing editorial board, Dermatology: Practical & Conceptual
2009- present contributing editor, www.derm101.com (monthly quizzes with clinic-pathologic correlation)
Clinical Trial Participation
09/05-05/06 Sub investigator, “An open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis”, Phase 3b, Schering-Plough
05/06-11/08 Principal investigator, “ Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-Type Psoriasis”, Phase 3b/4, Schering-Plough
06/06-07/11 Sub Investigator, "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis”, Phase 3, Centocor
09/2007-09/08 Subinvestigator, “A Randomized, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly For 12 weeks On Nail And Skin Symptoms In Patients With Nail Psoriasis And Plaque Psoriasis”, Phase 3b/4, Wyeth
05/08-02/2011 Principal Investigator, “Diabetes mellitus and other manifestations of metabolic syndrome in patients with psoriasis“, academic study
11/09-11/11 Principal Investigator, “A Rising Multiple-Dose Tolerability Safety, and Pharmacokinetic Study of Intravenous SCH 900222 in Patients With Psoriasis“, Phase 1, Schering-Plough/Merck
12/09-07/11 Principal Investigator, “An Exploratory Trial to Assess the Naturalistic Safety and Efficacy outcomes in Patients Transitioned to Ustekinumab from Previous Methotrexate Therapy (Transit) “, Phase 3b/4, Janssen-Cila
g 12/10-11/11 Principal Investigator, “Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH900222 in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis “, Phase 2, Schering-Plough/Merck
12/2012-ongoing Principal Investigator, “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis”, Phase 3, Eli-Lilly
Continuing Medical and Scientific Education Program
1998 “In vitro generation of epidermal Langerhans cells“, Department of Dermatology, Medical University of Vienna
1998 “In vitro differentiation of Langerhans cell-like dendritic cells“, Institute of Immunology, Medical University of Vienna
1999 “Facies leonine”, Department of Dermatology, Medical University of Vienna
2002 “Cloning of the mouse homologue of human langerin”, Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2003 “Characterization of a splice variant of mouse Langerin”, Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2003 “Identification and cloning of the mouse homologue of human langerin“, Department of Dermatology, Medical University of Vienna
2004 “Epidermolysis bullosa dystrophicans”, Department of Dermatology; Medical University of Vienna
2005 “Ulcus vulvae acutum Lipschuetz“, Department of Dermatology; Medical University of Vienna
2005 “Biologicals”, Department of Dermatology; Medical University of Vienna
2008 “Tuberculosis Screening prior to biological therapies”, Department of Dermatology; Medical University of Vienna
Lectures/Presentations; Invited Lectures and Publications in PDF
Comments are closed.